J. A. Sosman, K. B. Kim, L. Schuchter, R. Gonzalez, A. C. Pavlick et al., Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, vol.366, issue.8, pp.707-721, 2012.

E. Hartsough, Y. Shao, and A. E. Aplin, Resistance to RAF inhibitors revisited, J Invest Dermatol, vol.134, issue.2, pp.319-344, 2014.

P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, issue.26, pp.2507-2523, 2011.

H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature, vol.417, issue.6892, pp.949-54, 2002.

K. Trunzer, A. C. Pavlick, L. Schuchter, R. Gonzalez, G. A. Mcarthur et al., Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma, J Clin Oncol, vol.31, issue.14, pp.1767-74, 2013.

A. Diaz-lagares, E. Alegre, A. Arroyo, M. Gonzalez-cao, M. E. Zudaire et al., Evaluation of multiple serum markers in advanced melanoma, Tumour Biol, vol.32, issue.6, pp.1155-61, 2011.

M. R. Gray, M. Del-campo, S. Zhang, X. Zhang, H. Souza et al., Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab, Radiology, vol.270, issue.2, pp.425-459, 2014.

M. F. Sanmamed, S. Fernandez-landazuri, C. Rodriguez, R. Zarate, M. D. Lozano et al., Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors, Clin Chem, vol.61, issue.1, pp.297-304, 2015.

M. Schreuer, G. Meersseman, S. Van-den-herrewegen, Y. Jansen, I. Chevolet et al., Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/ MEK inhibitors, J Transl Med, vol.14, p.95, 2016.

E. Funck-brentano, J. C. Alvarez, C. Longvert, A. E. Beauchet, A. Funck-brentano et al., Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance, Ann Oncol, vol.26, issue.7, pp.1470-1475, 2015.

L. Goldwirt, I. Chami, J. P. Feugeas, C. Pages, F. Brunet-possenti et al., Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al, Ann Oncol, vol.27, issue.2, pp.363-367, 2016.

N. Kramkimel, A. Thomas-schoemann, L. Sakji, J. Golmard, G. Noe et al., Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma, Target Oncol, vol.11, issue.1, pp.59-69, 2016.

W. Zhang, D. Heinzmann, and J. F. Grippo, Clinical pharmacokinetics of Vemurafenib, Clin Pharmacokinet, 2017.

A. Puszkiel, M. White-koning, N. Dupin, N. Kramkimel, A. Thomasschoemann et al., Plasma vemurafenib exposure and pretreatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients, Pharmacol Res, vol.113, pp.709-727, 2016.

Y. Zhen, A. Thomas-schoemann, L. Sakji, P. Boudou-rouquette, N. Dupin et al., An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients, J Chromatogr B Analyt Technol Biomed Life Sci, vol.928, pp.93-100, 2013.

B. J. Hindson, K. D. Ness, D. A. Masquelier, P. Belgrader, N. J. Heredia et al., High-throughput droplet digital PCR system for absolute quantitation of DNA copy number, Anal Chem, vol.83, issue.22, pp.8604-8614, 2011.

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, L. Corre et al., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, issue.12, pp.1722-1753, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

C. A. Milbury, Q. Zhong, J. Lin, M. Williams, J. Olson et al., Determining lower limits of detection of digital PCR assays for cancer-related gene mutations, Biomol Detect Quantif, vol.1, issue.1, pp.8-22, 2014.

E. Zonta, F. Garlan, N. Pecuchet, K. Perez-toralla, O. Caen et al., Multiplex detection of rare mutations by Picoliter droplet based digital PCR: sensitivity and specificity considerations, PLoS One, vol.11, issue.7, p.159094, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02299556

A. C. Knol, A. Vallee, G. Herbreteau, J. M. Nguyen, E. Varey et al., Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline, Exp Dermatol, vol.25, issue.10, pp.783-791, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01408920

S. C. Tsao, J. Weiss, C. Hudson, C. Christophi, J. Cebon et al., Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations, Sci Rep, vol.5, p.11198, 2015.

M. Atefi, B. Titz, E. Avramis, C. Ng, D. J. Wong et al., Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma, Mol Cancer, vol.14, p.27, 2015.

M. S. Carlino, L. E. Haydu, H. Kakavand, A. M. Menzies, A. L. Hamilton et al., Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma, Br J Cancer, vol.111, issue.2, pp.292-301, 2014.

C. M. Nijenhuis, A. D. Huitema, C. Blank, J. B. Haanen, J. V. Van-thienen et al., Clinical pharmacokinetics of Vemurafenib in BRAF-mutated melanoma patients, J Clin Pharmacol, vol.57, issue.1, pp.125-133, 2017.

A. Ribas, W. Zhang, I. Chang, K. Shirai, M. S. Ernstoff et al., The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics, J Clin Pharmacol, vol.54, issue.4, pp.368-74, 2014.